Clinical trials: Diabetes Type I
Non-Insulin-Dependent Diabetes Mellitus, Obesity
Efficacy and Safety of ATL-962 in Obese Diabetics
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients
- Trial name
- NCT00156897
- Testing
- ATL-962, Orlistat
- Where
- 37 sites in Denmark, Finland and 3 more
- Volunteers
- 600 people
- Sponsor
- Alizyme
Type 1 Diabetes, Type 2 Diabetes
Adult Accuracy Study of the Enlite 3 Glucose Sensor
The purpose of this study is to demonstrate the performance of the Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen and used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years with type 1…
- Trial name
- E3 (NCT02246582)
- Testing
- Enlite 3, Guardian Mobile App, 640G Insulin Pump
- Where
- 6 sites in United States
- Volunteers
- 118 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients
This trial is a multi-center, open-label, randomized, parallel group trial in adult patients with T1DM comparing the efficacy and safety of GP40071 (insulin aspart, GEROPHARM) with that of NovoRapid®.
- Trial name
- NCT04079413
- Testing
- GP40071, NovoRapid® Penfill®
- Where
- 14 sites in Russia
- Volunteers
- 264 people
- Sponsor
- Geropharm
Diabetes, Diabetes Mellitus, Type 1
Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma
This trial is conducted in Europe, Asia, Oceania and the United States of America (USA). This is a one-year clinical trial to compare the safety of inhaled preprandial human insulin to subcutaneous insulin aspart in subjects with…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
- Trial name
- iINHALE 9 (NCT00523042)
- Testing
- insulin aspart, inhaled human insulin
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 10 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Diabetes Mellitus ( Type 1 and Type 2)
PMCF Study of GX-01S CGM in Adults With Diabetes
This clinical study evaluates the GX-01S Continuous Glucose Monitoring (CGM) System in adults with Type 1 or Type 2 diabetes. CGM systems measure glucose levels continuously throughout the day, providing real-time information…
- Trial name
- PROMISE-GX (NCT07802327)
- Testing
- GX-01S Continuous Glucose Monitoring System
- Volunteers
- 100 people
- Sponsor
- MicroTech Medical（Hangzhou）Co.,Ltd.
Type 1 Diabetes Mellitus, Type 1 Diabetes
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.
- Conditions
- Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes
- Trial name
- NCT00690066
- Testing
- PROCHYMAL®
- Where
- 20 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mesoblast, Inc.
Type 1 Diabetes Mellitus
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
Primary Objective: To demonstrate the non-inferiority of insulin glargine 300 units per milliliter (U/ml) in comparison to insulin degludec 100 U/ml on glycemic control and variability in participants with diabetes mellitus.
- Trial name
- inRange (NCT04075513)
- Testing
- Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs
- Where
- 7 sites in United States, Brazil and 5 more
- Volunteers
- 343 people
- Sponsor
- Sanofi
Type 1 Diabetes
ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion.
This study will evaluate the safety and performance of ENCRT-103-hPI, which is a cargo of primary islets inside Encellin's ENC-103-CED.
- Trial name
- NCT07680673
- Testing
- ENCRT-103-hPI encompasses the ENC-103 device, which will be implanted once loaded with primary islet cargo.
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Encellin
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo.
- Trial name
- Tremelimumab (NCT01843374)
- Testing
- Tremelimumab
- Where
- 104 sites in United States, Australia and 17 more
- Volunteers
- 571 people
- Sponsor
- MedImmune LLC
Diabetes, Diabetes Mellitus, Type 1
NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
This trial is conducted in the United States of America (USA). The aim of this trial is to assess control of blood sugar, safety, and patient acceptance of insulin aspart compared to insulin lispro, both in insulin pumps, in…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00095446
- Testing
- insulin aspart
- Where
- United States
- Volunteers
- 513 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study
This study will evaluate the accuracy and safety of the RIGHTEST iFree 2 Continuous Glucose Monitoring (CGM) System in pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Diabetes, Gestational
- Trial name
- NCT07889388
- Testing
- RIGHTEST iFree 2 Continuous Glucose Monitoring System
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- Bionime Corporation
Diabetes Mellitus, Type 1
Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy and the safety of insulin glulisine in type I Diabetes Melittus (DM) patients Secondary Objective: To evaluate the insulin glulisine doses To assess the patient satisfaction
- Trial name
- PORTAL 1 (NCT00964574)
- Testing
- INSULIN GLULISINE (HMR1964), INSULIN GLARGINE
- Where
- Belarus
- Volunteers
- 68 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients
The objective of this trial is to investigate the pharmacokinetics and pharmacodynamics of linagliptin (BI 1356) 5 mg administered orally in patients with Type 2 diabetes mellitus of African American origin.
- Trial name
- NCT00935220
- Testing
- linagliptin QD (once daily) for 7 days
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type I
Dose-Exposure-Response in Type 1 Diabetes Mellitus
To investigate the dose-exposure-response relationship of insulin glulisine (HMR1964) after single subcutaneous injections of 0.075, 0.15 and 0.3 U/kg body weight with the euglycaemic clamp technique using the Biostator (TM).
- Trial name
- NCT00368394
- Testing
- Insulin glulisine
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in elderly and younger adults with type 1 diabetes mellitus. Screening is required within 28 days prior to the start of the study.
- Trial name
- NCT03166124
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study in Participants With Type 1 Diabetes Mellitus
The purpose of this study is: To compare the blood sugar control of LY2605541 with insulin glargine after 78 weeks of treatment.
- Trial name
- IMAGINE 1 (NCT01481779)
- Testing
- Glargine, LY2605541, Insulin Lispro
- Where
- 51 sites in United States, Austria and 7 more
- Volunteers
- 455 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of…
- Trial name
- NCT02131246
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Diabetes Type 1
Feasibility Study of an Integrated Sensor and Infusion Set
The purpose of this study is to collect performance data on the integrated sensor and infusion set during 3 days of use and demonstrate performance adequacy of the Integrated sensor and infusion set with glucose sensing and…
- Trial name
- NCT01770561
- Testing
- Integrated sensor and infusion set.
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Medtronic Diabetes R&D Denmark
Diabetes Mellitus, Type 1
PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients
Primary objectives: To demonstrate biosimilarity with regard to the total and maximum pharmacokinetic exposure during one dosing interval (AUC ins. 0-24h, Cins.
- Trial name
- NCT04236895
- Testing
- Gan & Lee Insulin Glargine Injection
- Where
- 2 sites in Germany
- Volunteers
- 114 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 1 Diabetes
A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD13-02 in patients with aT1DM
- Trial name
- NCT07142161
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.